Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 5
1963 4
1964 1
1966 1
1971 1
1972 1
1973 4
1979 1
1984 1
1985 1
1989 1
1990 5
1991 1
1992 2
1993 1
1994 2
1997 1
1998 3
1999 4
2000 2
2001 3
2002 5
2003 2
2004 2
2005 5
2006 10
2007 4
2008 8
2009 8
2010 7
2011 11
2012 18
2013 19
2014 13
2015 13
2016 21
2017 18
2018 10
2019 16
2020 13
2021 19
2022 11
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Antiretropulsion devices.
Cabrera FJ, Preminger GM, Lipkin ME. Cabrera FJ, et al. Curr Opin Urol. 2014 Mar;24(2):173-8. doi: 10.1097/MOU.0000000000000032. Curr Opin Urol. 2014. PMID: 24418744 Review.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
The Emerging Role of Nanotechnology in Cell and Organ Transplantation.
Tasciotti E, Cabrera FJ, Evangelopoulos M, Martinez JO, Thekkedath UR, Kloc M, Ghobrial RM, Li XC, Grattoni A, Ferrari M. Tasciotti E, et al. Among authors: cabrera fj. Transplantation. 2016 Aug;100(8):1629-38. doi: 10.1097/TP.0000000000001100. Transplantation. 2016. PMID: 27257995 Free PMC article. Review.
Side effects of ranitidine.
Vial T, Goubier C, Bergeret A, Cabrera F, Evreux JC, Descotes J. Vial T, et al. Among authors: cabrera f. Drug Saf. 1991 Mar-Apr;6(2):94-117. doi: 10.2165/00002018-199106020-00002. Drug Saf. 1991. PMID: 2043287 Review.
241 results